Liraglutide 3.0 mg improves fatty liver disease markers in obese patients across South Korean hospitals
In 503 obese patients across 10 South Korean hospitals, liraglutide 3.0 mg continuously improved liver enzyme levels, fatty liver scores, and insulin sensitivity over 6 months with no serious adverse events.
Quick Facts
What This Study Found
Liraglutide 3.0 mg reduced AST from 33.2 to 27.4 IU/L (p<0.001), ALT from 41.6 to 30.6 IU/L (p<0.001), HSI from 44.7 to 42.2 (p<0.001), and NAFLD liver fat score from 2.12 to 0.43 (p<0.001) over 6 months. Insulin sensitivity improved from 4.38 to 4.72 (p<0.001).
Key Numbers
503 enrolled, 101 completed 6 months. AST dropped from 33.2 to 27.4 IU/L (P < 0.001). ALT dropped from 41.6 to 30.6 IU/L (P < 0.001). HSI dropped from 44.7 to 42.2 (P < 0.001). NAFLD liver fat score dropped from 2.12 to 0.43 (P < 0.001).
How They Did This
Prospective real-world multicenter study across 10 tertiary hospitals in South Korea. 503 adults with BMI ≥27 and obesity-related comorbidities, followed at 2, 4, and 6 months with anthropometric and biochemical assessments.
Why This Research Matters
MASLD affects a large proportion of people with obesity and can progress to cirrhosis and liver cancer. Demonstrating that a GLP-1 peptide drug improves liver health markers in real clinical practice—not just controlled trials—supports its use as a dual-purpose treatment for obesity and liver disease.
The Bigger Picture
This adds to mounting evidence that GLP-1 peptide drugs benefit liver health alongside weight and metabolic improvements. As MASLD affects up to 30% of the global population, the potential for GLP-1 drugs to address liver disease concurrently with obesity could significantly expand their clinical impact.
What This Study Doesn't Tell Us
No control group (single-arm observational study). Significant attrition: 503 enrolled but only 101 completed 6 months. Surrogate markers used rather than direct liver imaging or biopsy. Results may partly reflect weight loss effects rather than direct hepatic action.
Questions This Raises
- ?Does liraglutide improve actual liver histology (biopsy-confirmed) in MASLD, or only surrogate blood markers?
- ?How does liraglutide compare to semaglutide or resmetirom for MASLD treatment?
- ?What explains the high dropout rate from 503 to 101 patients over 6 months?
Trust & Context
- Key Stat:
- NAFLD score: 2.12 → 0.43 Liver fat score dropped 80% over 6 months of liraglutide treatment across 10 South Korean hospitals
- Evidence Grade:
- Multicenter real-world observational study with significant sample size. Provides practical clinical evidence but lacks control group and uses surrogate markers. High attrition limits long-term conclusions.
- Study Age:
- Published in 2025; represents current real-world evidence for GLP-1 drugs in fatty liver disease.
- Original Title:
- Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.
- Published In:
- Annals of nutrition & metabolism, 81(6), 328-337 (2025)
- Authors:
- Park, Jungha, Kim, Jin-Wook, Lim, Soo(4)
- Database ID:
- RPEP-12960
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can liraglutide treat fatty liver disease?
This real-world study showed liraglutide 3.0 mg significantly improved blood markers of fatty liver disease over 6 months, including liver enzymes (ALT, AST) and fatty liver scores. While not a direct liver treatment, its effects on weight, insulin sensitivity, and liver markers suggest it can benefit both conditions simultaneously.
How quickly did liver markers improve with liraglutide?
Improvements were continuous from month 2 through month 6, with liver enzymes, fatty liver scores, and insulin sensitivity all showing statistically significant improvements at each time point. The NAFLD liver fat score showed the most dramatic change, dropping by about 80%.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12960APA
Park, Jungha; Kim, Jin-Wook; Lim, Soo. (2025). Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.. Annals of nutrition & metabolism, 81(6), 328-337. https://doi.org/10.1159/000547347
MLA
Park, Jungha, et al. "Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.." Annals of nutrition & metabolism, 2025. https://doi.org/10.1159/000547347
RethinkPeptides
RethinkPeptides Research Database. "Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associ..." RPEP-12960. Retrieved from https://rethinkpeptides.com/research/park-2025-impact-of-liraglutide-30
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.